WEED Canopy Growth Corporation
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-related products for medical and adult use in Canada, Germany, the United States, and internationally. The company operates through two segments, Cannabis and Storz & Bickel. It also provides vaporizers and accessories; dried flower and pre-rolled joints, oil, and vapes and beverages; extracts and concentrates, such as softgel capsules; and cannabis edibles, including gummies. In addition, the company operates e-commerce shop; medical cannabis online distribution platform; and an online medical cannabis clinic. It sells its products under the Tweed, 7ACRES, Deep Space, HiWay, Maitri, Twd., Spectrum Therapeutics, Canopy Medical, Abba Medix, Storz & Bickel, Wana, and Claybourne, Apollo, Canada House, R'belle, LowKey, MTL Cannabis, DeeLish, DOJA brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Canopy Growth (TSE: WEED)
›
Canopy Growth (TSE: WEED) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 1,128 employees.
The shares were at 0.6900 CAD on 19 November 2026, down 57.9% over 52 weeks. Its 52-week range is 0.6650 CAD to 3.280 CAD: the price is 79.0% below the high and 3.8% above the low.
Its market capitalisation is 310.23M CAD.
Canopy Growth reports return on equity of -37.7%, an operating margin of -21.8% and revenue up 22.0% year over year.
It holds more cash than debt, a net cash position of 39.02M CAD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 6 analysts cover the stock, with an average rating of Hold; their mean price target of 1.928 CAD is 179.5% above the current price. The next earnings report is expected on 5 February 2027.